Opinion|Videos|December 2, 2024

Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy

Author(s)Ahmad A. Tarhini, MD, PhD, Hussein Abdul-Hassan Tawbi, MD, PhD

Panelists discuss how treatment decisions in metastatic melanoma involve balancing the benefits of immunotherapy versus targeted therapy, taking into account factors such as tumor genetics, patient response, and tolerability.

Episodes in this series

EP. 1 Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy

EP. 1 Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy

EP. 2 Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma

EP. 2 Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma

EP. 3 Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067

EP. 3 Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067

EP. 4 Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma

EP. 4 Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma

EP. 5 Insight on Treating Patients With Melanoma With Brain Metastases

EP. 5 Insight on Treating Patients With Melanoma With Brain Metastases

EP. 6 Expert Insight on Using Dual-IO Regimens for Melanoma in Real-World Practice

EP. 6 Expert Insight on Using Dual-IO Regimens for Melanoma in Real-World Practice

EP. 7 Potential Roles for First-Line Targeted Therapy for Advanced Melanoma

EP. 7 Potential Roles for First-Line Targeted Therapy for Advanced Melanoma

EP. 8 Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced Melanoma

EP. 8 Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced Melanoma

EP. 9 Nivolumab Combinations Show Best Treatment Options for Advanced Melanoma

EP. 9 Nivolumab Combinations Show Best Treatment Options for Advanced Melanoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

The FDA approved the first and only photodynamic therapy for the treatment of a skin cancer.

September 14th, 2026

FDA Approves Topical Gel for Superficial Basal Cell Carcinoma

The FDA approved the first and only photodynamic therapy for the treatment of a skin cancer.

Trending on CancerNetwork

Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC

Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma

FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026